[ad_1]
According to the BBC report, the UK Medicines and Healthcare Products Regulatory Agency reported that the candidate vaccine “BNT162b2” is safe for widespread use.
Thus, the UK became the first country to approve a candidate vaccine developed against COVID-19.
Following approval, vaccination of high priority groups in the UK is expected to begin next week.
Britain had previously entered into a pre-agreement to purchase 40 million doses of the vaccine.
FIRST COVID-19 VACCINE REGISTERED
Messenger Ribo Nucleic Acid (mRNA) vaccine candidate became the first COVID-19 vaccine to be registered in the world.
The vaccine was approved by completing preclinical development studies and 3-phase clinical trials in just 10 months.
The vaccine aims to activate immunoglobulin G antibodies that bind uptake with blood sugar enzymes that inactivate COVID-19 thanks to the composition of RNA in its formula and to increase CD4 + and CD8 + glycoproteins that create an immune response at the cellular level.
Pfizer in the United States, pharmaceutical companies Fosun Pharma in China received the production license for the vaccine candidate, after the 1st and 2nd phase clinical trials were conducted in Germany on July 27, 30,000 healthy people in countries between including USA, Argentina and Germany. Phase three clinical trials were initiated with the aim of participating in volunteers.
95 PER CENT EFFECTIVE AGAINST VIRUS
Pfizer and BioNTech reported that they completed their Phase 3 clinical trials on November 18 and that the vaccine candidate was 95% effective in providing immunity against the virus.
The companies had applied to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to allow immediate use of the candidate vaccine.
MANY COUNTRIES HAVE PREVENTIVE AGREEMENTS
The companies have entered into agreements with the US, the European Union (EU), the UK, Canada and Japan for the supply of the vaccine. The US government has pledged $ 1.95 billion to purchase 100 million doses of the vaccine if the vaccine candidate is successful, while the European Commission has a pre-contracted contract to purchase 300 million doses. vaccine, 40 million doses in the UK, 20 million doses in Canada and 120 million doses in Japan. had signed.
25 MILLION DOSES OF TURKEY TAKE THE PLAN
Health Minister Fahrettin Koca, Turkey’s vaccine candidate, announced on November 25 that it had conducted negotiations to purchase 25 million doses in the winter months, including 1 million in range.
The company expects to produce 100 million doses from the vaccine by the end of 2020 and about 1.3 billion doses by the end of 2021.
.
[ad_2]
Source link
